Catalyst Reports Q4 Revenue of $152.6M, Beating Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy CPRX?
Reports Q4 revenue $152.6M, consensus $142.75M. "Our 2025 performance is a reflection of Catalyst's organic growth of our promoted products, FIRDAPSE and AGAMREE, and our continued commercial success. Achieving total revenues for 2025 of $589.0 million demonstrates the strength of our scalable business model and our continued dedication to patient care," said Rich Daly, President and CEO, Catalyst. "Looking forward, our core commercial capabilities and our exploration of lifecycle management opportunities within our portfolio will continue to create value. We also continue to execute our business development strategy, which includes recently widening our aperture to look at products in development that have an established proof of concept. Based on our recent progress and considering the growth opportunities that we see for both FIRDAPSE and AGAMREE, we anticipate 2026 will prove to be another exceptional year, as reflected in our 2026 revenue guidance."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CPRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CPRX
Wall Street analysts forecast CPRX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 31.150
Low
33.00
Averages
34.00
High
35.00
Current: 31.150
Low
33.00
Averages
34.00
High
35.00
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Catalyst Pharmaceuticals to Announce Q1 Earnings on May 11
- Earnings Announcement: Catalyst Pharmaceuticals is set to release its Q1 2023 earnings on May 11 after market close, with consensus EPS estimate at $0.64, reflecting a 5.9% year-over-year decline, while revenue is projected at $148.18 million, indicating a 5.1% increase, which could significantly impact investor sentiment.
- Historical Performance: Over the past two years, Catalyst has consistently beaten EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's stability in financial performance and its ability to manage market expectations effectively.
- Estimate Revision Trends: In the last three months, EPS estimates have seen three upward revisions and one downward revision, while revenue estimates have experienced three upward and two downward revisions, indicating fluctuations in analyst confidence regarding the company's future performance, which may influence investor decisions.
- Acquisition Interest: Catalyst's stock surged on reports of interest from Angelini Pharma for a $4.1 billion acquisition, which could present new strategic opportunities for the company while potentially impacting its future market positioning and financial health.
See More
Catalyst Pharmaceuticals Agrees to $4.1B Acquisition by Angelini Pharma
- Acquisition Agreement: Catalyst Pharmaceuticals has entered into a definitive agreement with Angelini Pharma for a $4.1 billion acquisition, expected to close in Q3 pending shareholder and regulatory approvals, highlighting the company's significant position in industry consolidation.
- Patent Litigation Resolution: The full settlement of FIRDAPSE patent litigation secures U.S. market exclusivity until January 2035, enhancing product market protection and boosting investor confidence in Catalyst's future.
- Strong Stock Performance: Catalyst's stock has risen 24.7% over the past month and 34.6% year-to-date, reflecting positive market sentiment regarding the acquisition and recognition of the company's growth potential.
- Investor Focus: As the deal progresses, investors should monitor the spread between the stock price and the implied deal value, as well as updates on shareholder and regulatory approvals, which will directly impact the transaction's completion and the company's strategic direction.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) regarding its sale to Angelini Pharma S.p.A. for $31.50 per share, as potential violations of shareholder rights may exist, prompting shareholders to understand their rights and options.
- Transaction Details: TruBridge, Inc. (NASDAQ:TBRG) is being sold to Inventurus Knowledge Solutions, Inc. for $26.25 per share in cash, with Halper Sadeh LLC urging shareholders to be aware of potential legal rights and compensation opportunities.
- Merger Impact: Following the proposed transaction, Modiv Industrial, Inc. (NYSE:MDV) shareholders are expected to own approximately 11% of the combined company, and Halper Sadeh LLC may seek increased compensation for shareholders.
- Legal Support: Halper Sadeh LLC represents investors globally, focusing on legal remedies for securities fraud and corporate misconduct, emphasizing its successful track record in implementing corporate reforms and recovering funds for defrauded investors.
See More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion
- Acquisition Details: Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, valuing the deal at approximately $4.1 billion, with unanimous board approval from both companies, expected to close in Q3 2026, marking Angelini's formal entry into the U.S. market.
- Strategic Importance: This acquisition enhances Angelini's long-term strategy in brain health and rare diseases, as Catalyst's portfolio will integrate with Angelini's brain health assets to build a next-generation rare disease platform, supporting balanced expansion across the U.S. and Europe.
- Financing Arrangement: The deal will be financed with participation from Blackstone funds and international partners, with BNP Paribas serving as Sole Global Coordinator and Underwriter, reflecting strong market confidence and support for the transaction.
- Patent Litigation Resolution: Catalyst also announced a settlement with Hetero Labs Ltd. regarding FIRDAPSE patent litigation, ensuring that a generic version will not be marketed in the U.S. before January 2035, further solidifying its market position and eliminating potential legal risks.
See More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion
- Acquisition Overview: Angelini Pharma has reached an agreement to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, totaling approximately $4.1 billion, representing a 28% premium over the 30-day volume-weighted average trading price as of April 22, 2026, marking Angelini Pharma's entry into the U.S. market.
- Strategic Importance: This acquisition not only reinforces Angelini Pharma's commitment to rare diseases but also integrates its presence in the U.S. market with its core business in Europe, expected to drive global growth for the company.
- Financing Structure: The transaction will be financed through a combination of cash and debt, with BNP Paribas acting as the Sole Global Coordinator and Underwriter, ensuring smooth execution of the deal, which is anticipated to close in the third quarter of 2026.
- Product Integration Plans: Following the acquisition, Angelini Pharma intends to merge Catalyst's product portfolio with its expertise in Brain Health to develop a next-generation therapeutic platform for rare diseases, enhancing patient care and innovation capabilities.
See More
Hetero Labs Secures License for FIRDAPSE Generic
- Patent Litigation Settlement: Catalyst Pharmaceuticals has reached a settlement agreement with Hetero Labs, concluding patent litigation over FIRDAPSE, ensuring that Hetero cannot market its generic version in the U.S. until at least January 2035, thereby reducing competitive risks for Catalyst.
- Market Access Restrictions: Under the agreement, Hetero's generic FIRDAPSE must receive FDA approval and can only launch earlier under specific circumstances, providing Catalyst with a longer exclusivity period and enhancing the stability of its commercial strategy.
- Legal Compliance Review: The settlement agreement will be submitted for review to the U.S. Federal Trade Commission and Department of Justice, ensuring compliance and maintaining fair competition in the market, further solidifying Catalyst's position in the rare disease treatment sector.
- Historical Litigation Context: Catalyst has previously settled similar litigation with multiple pharmaceutical companies, such as Lupin and Teva, demonstrating its firm stance on protecting FIRDAPSE patents and boosting investor confidence in its future growth prospects.
See More
Catalyst Pharmaceuticals to Announce Q1 Earnings on May 11
- Earnings Announcement: Catalyst Pharmaceuticals is set to release its Q1 2023 earnings on May 11 after market close, with consensus EPS estimate at $0.64, reflecting a 5.9% year-over-year decline, while revenue is projected at $148.18 million, indicating a 5.1% increase, which could significantly impact investor sentiment.
- Historical Performance: Over the past two years, Catalyst has consistently beaten EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's stability in financial performance and its ability to manage market expectations effectively.
- Estimate Revision Trends: In the last three months, EPS estimates have seen three upward revisions and one downward revision, while revenue estimates have experienced three upward and two downward revisions, indicating fluctuations in analyst confidence regarding the company's future performance, which may influence investor decisions.
- Acquisition Interest: Catalyst's stock surged on reports of interest from Angelini Pharma for a $4.1 billion acquisition, which could present new strategic opportunities for the company while potentially impacting its future market positioning and financial health.
See More
Catalyst Pharmaceuticals Agrees to $4.1B Acquisition by Angelini Pharma
- Acquisition Agreement: Catalyst Pharmaceuticals has entered into a definitive agreement with Angelini Pharma for a $4.1 billion acquisition, expected to close in Q3 pending shareholder and regulatory approvals, highlighting the company's significant position in industry consolidation.
- Patent Litigation Resolution: The full settlement of FIRDAPSE patent litigation secures U.S. market exclusivity until January 2035, enhancing product market protection and boosting investor confidence in Catalyst's future.
- Strong Stock Performance: Catalyst's stock has risen 24.7% over the past month and 34.6% year-to-date, reflecting positive market sentiment regarding the acquisition and recognition of the company's growth potential.
- Investor Focus: As the deal progresses, investors should monitor the spread between the stock price and the implied deal value, as well as updates on shareholder and regulatory approvals, which will directly impact the transaction's completion and the company's strategic direction.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) regarding its sale to Angelini Pharma S.p.A. for $31.50 per share, as potential violations of shareholder rights may exist, prompting shareholders to understand their rights and options.
- Transaction Details: TruBridge, Inc. (NASDAQ:TBRG) is being sold to Inventurus Knowledge Solutions, Inc. for $26.25 per share in cash, with Halper Sadeh LLC urging shareholders to be aware of potential legal rights and compensation opportunities.
- Merger Impact: Following the proposed transaction, Modiv Industrial, Inc. (NYSE:MDV) shareholders are expected to own approximately 11% of the combined company, and Halper Sadeh LLC may seek increased compensation for shareholders.
- Legal Support: Halper Sadeh LLC represents investors globally, focusing on legal remedies for securities fraud and corporate misconduct, emphasizing its successful track record in implementing corporate reforms and recovering funds for defrauded investors.
See More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion
- Acquisition Details: Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, valuing the deal at approximately $4.1 billion, with unanimous board approval from both companies, expected to close in Q3 2026, marking Angelini's formal entry into the U.S. market.
- Strategic Importance: This acquisition enhances Angelini's long-term strategy in brain health and rare diseases, as Catalyst's portfolio will integrate with Angelini's brain health assets to build a next-generation rare disease platform, supporting balanced expansion across the U.S. and Europe.
- Financing Arrangement: The deal will be financed with participation from Blackstone funds and international partners, with BNP Paribas serving as Sole Global Coordinator and Underwriter, reflecting strong market confidence and support for the transaction.
- Patent Litigation Resolution: Catalyst also announced a settlement with Hetero Labs Ltd. regarding FIRDAPSE patent litigation, ensuring that a generic version will not be marketed in the U.S. before January 2035, further solidifying its market position and eliminating potential legal risks.
See More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion
- Acquisition Overview: Angelini Pharma has reached an agreement to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, totaling approximately $4.1 billion, representing a 28% premium over the 30-day volume-weighted average trading price as of April 22, 2026, marking Angelini Pharma's entry into the U.S. market.
- Strategic Importance: This acquisition not only reinforces Angelini Pharma's commitment to rare diseases but also integrates its presence in the U.S. market with its core business in Europe, expected to drive global growth for the company.
- Financing Structure: The transaction will be financed through a combination of cash and debt, with BNP Paribas acting as the Sole Global Coordinator and Underwriter, ensuring smooth execution of the deal, which is anticipated to close in the third quarter of 2026.
- Product Integration Plans: Following the acquisition, Angelini Pharma intends to merge Catalyst's product portfolio with its expertise in Brain Health to develop a next-generation therapeutic platform for rare diseases, enhancing patient care and innovation capabilities.
See More
Hetero Labs Secures License for FIRDAPSE Generic
- Patent Litigation Settlement: Catalyst Pharmaceuticals has reached a settlement agreement with Hetero Labs, concluding patent litigation over FIRDAPSE, ensuring that Hetero cannot market its generic version in the U.S. until at least January 2035, thereby reducing competitive risks for Catalyst.
- Market Access Restrictions: Under the agreement, Hetero's generic FIRDAPSE must receive FDA approval and can only launch earlier under specific circumstances, providing Catalyst with a longer exclusivity period and enhancing the stability of its commercial strategy.
- Legal Compliance Review: The settlement agreement will be submitted for review to the U.S. Federal Trade Commission and Department of Justice, ensuring compliance and maintaining fair competition in the market, further solidifying Catalyst's position in the rare disease treatment sector.
- Historical Litigation Context: Catalyst has previously settled similar litigation with multiple pharmaceutical companies, such as Lupin and Teva, demonstrating its firm stance on protecting FIRDAPSE patents and boosting investor confidence in its future growth prospects.
See More
